GATA3 and breast carcinoma: Therefore, whether or not GATA3 mutant breast cancers have better clinical outcomes than ER+ GATA3 wild type tumors, it remains possible that mutant Gata3 or its downstream effectors could be rational targets for breast cancer therapy.